viewProactive Group

Investor Update: Allergy Therapeutics receives multi-million-dollar settlement

Top stories from the Proactive Investors UK newsroom.

Allergy Therapeutics (LON:AGY) has accepted US$7.6mln in settlement of a dispute over the procedures used for a US grass pollen vaccine trial. Allergy blamed the inconclusive trial results on the way the study was carried out.

Graphene specialist Directa Plus (LON:DCTA) has been awarded a patent in the US for its manufacturing process that just uses water with no chemicals. Directa said this sustainability was already proving attractive to US companies.

BlueJay Mining’s (LON:JAY) Dundas minerals sands project in Greenland is worth US$83mln over a nine-year mine life according to a pre-feasibility study. Costs to build the mine and infrastructure are estimated at US$245mln.

Kingfisher has appointed a veteran of French supermarket Carrefour as its new chief executive in the autumn.

Serco’s revenues this year will be at the top end of expectations while orders have also climbed to £3bn. The outsourcer left trading profit guidance unchanged at £105mln.

Boeing’s hopes of getting clearance for its troubled 737 Max aircraft have been dashed again as US regulators have unearthed another problem. The potential risk was discovered during simulator tests.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Archer Materials begins next phase in the development of their 12CQ Chip

Archer Materials (ASX: AXE) Chief Executive Officer Dr Mohammad Choucair shared the news with Steve Darling from Proactive that company has entered the next and very exciting phase of their development of the 12CQ Chip for Quantum Computing. Choucair telling Proactive what this next...

2 hours, 54 minutes ago

2 min read